| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 96.74 | -0.30 (-0.31%) | 80.09 - 102.04 | 755.9 thousand (Below Avg) |
Market data as of 4:00PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 95.81 |
|---|---|
| Previous Close | 97.04 |
| Day's Range | 95.81 - 97.12 |
| Market Cap | 17.9B |
| Avg Volume (10 Day) | 836.4K |
| Price/Earnings (Trailing 12 Mo.) | 18.4x |
| Earnings Per Share (Trailing 12 Mo.) | 4.66 |
| Dividend Yield | 0.438 (0.54%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Pass |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Pass |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Pass |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases
PR Newswire - Monday 05/20/2013 7:00 AM ET
Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
PR Newswire - Friday 05/17/2013 10:00 AM ET
Shire Wins Patent Trial Against Watson Concerning LIALDA®
PR Newswire - Thursday 05/09/2013 12:20 PM ET
Acceleron and Shire Conclude Collaboration on ACE-031
Business Wire - Thursday 05/02/2013 10:08 AM ET
New Chief Executive Reports Q1 Results and Sets out Strategy for Growth
PR Newswire - Thursday 05/02/2013 7:00 AM ET
Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Children and Adolescents with ADHD
PR Newswire - Wednesday 05/01/2013 3:45 PM ET
Shire Settles All Pending Litigation with Actavis and Watson Concerning INTUNIV®
PR Newswire - Thursday 04/25/2013 10:16 AM ET
Actavis Reaches Agreement with Shire to Launch a Generic Version of Intuniv® in December 2014
PR Newswire - Thursday 04/25/2013 9:28 AM ET
| SHPG | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 4.67% | |
| Net Income Growth (1yr) | 23.94% | |
| Total Debt/Equity | 0.29 | |
| LT Debt/Equity | 0.29 | |
| Earnings Yield | 5.43% | |
| Price/Sales | 3.90 |
| Company | Last | Change |
|---|---|---|
| Alcobra Ltd | 7.21 | -4.50% |
| Vertex Pharmaceuticals Inc | 78.48 | +0.06% |
| Alexion Pharmaceuticals Inc | 99.88 | -0.69% |
| Regeneron Pharmaceuticals Inc | 254.87 | -2.88% |
| BioMarin Pharmaceutical Inc | 65.76 | +0.32% |
Data is delayed by at least 15 min.